Trending...
- Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
- American Garden Rose Selections™ Announces 2027 Winners
- ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
BEAT Appoints Passionate CEO Robert Eno with Multiple Breakthrough Products and Over 30 Years of Industry Experience
SANTA CLARA, Calif. - PennZone -- Creating First Ever Cable-Free 12-Lead ECG Capable of Capturing Cardiac Electrical Signals from Three Dimensions.
Technology Designed for Portable Devices to Deliver Actionable Heart Intelligence Anywhere.
HeartBeam, Inc. (Stock Symbol: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. BEAT is creating the first ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This BEAT platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. BEAT holds 13 US and 4 international issued patents related to technology enablement.
BEAT Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
On October 17th BEAT announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined BEAT as President in January 2023 and will lead as the Company continues to work towards securing the foundational FDA 510(k) clearance for its vector-based technology and prepares for commercialization and growth.
More on The PennZone
As part of the long-planned transition, Branislav Vajdic, Ph.D., BEAT Founder and current CEO, will move into the role of President. In this role, Dr. Vajdic will focus on further innovating on the groundbreaking BEAT vector-based technology, driving research and development efforts, and advancing artificial intelligence (AI) applications.
The BEAT core vector-based technology captures the heart's electrical signals from three dimensions to provide total heart intelligence. The first application of the BEAT technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The BEAT system is currently under review with the FDA.
With over 30 years of experience, Mr. Eno, age 57, is a passionate leader who has created go-to-market strategies for multiple breakthrough products including noninvasive FFRCT for diagnosing coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation, and intravascular brachytherapy. Before joining BEAT, Mr. Eno was Chief Executive Officer of Preview Medical, a diagnostic equipment company creating a new category of real-time, in vivo tissue classification for solid tumor cancers, using machine learning and proprietary optical signals. Previously, he was Senior Vice President of Marketing for HeartFlow, leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. Mr. Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa.
More on The PennZone
Dr. Lance Myers Appointed as Chief AI Scientist
On September 24th BEAT announced the appointment of Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, as Chief Artificial Intelligence (AI) Scientist. In this newly created position, Dr. Myers will play a pivotal role in guiding how AI is applied to the Company's core technology.
Most recently, Dr. Myers served as AI Advisor to BEAT. Previously, he was the Head of Cardiovascular Devices at Verily Life Sciences (formerly Google Life Sciences), where he led a team developing a novel heart failure monitoring solution. Prior to that, he was the Head of Data Science at Verily and built a high-performance AI organization with teams in computational biology, medical device and biosensor algorithms, digital biomarkers, health informatics and digital pathology. He has also held leadership roles at XAI.health, Sentrian, VivoSense, Boston Neurosciences and Vivometrics. He currently serves as a board member for VivoSense and is on the scientific advisory boards of Acorai, XAI.health and Bryte. Dr. Myers received his PhD in Biomedical Engineering from the University of Cape Town in South Africa.
Media Contact
Company Name: HeartBeam, Inc.
Contact Person: Timothy Cruickshank
Email: ir.heartbeam.com
Phone: 408-899-4443
Website: www.HeartBeam.co m
Home Country: United States
Disclaimer and Disclosure: www. aibrandnetwork.com
Technology Designed for Portable Devices to Deliver Actionable Heart Intelligence Anywhere.
HeartBeam, Inc. (Stock Symbol: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. BEAT is creating the first ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This BEAT platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. BEAT holds 13 US and 4 international issued patents related to technology enablement.
BEAT Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
On October 17th BEAT announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined BEAT as President in January 2023 and will lead as the Company continues to work towards securing the foundational FDA 510(k) clearance for its vector-based technology and prepares for commercialization and growth.
More on The PennZone
- Champions for Education to Honor United Way of the Greater Lehigh Valley and Induct Three Leaders
- Holiday Gambling Spending Expected to Rise 12% in December
- RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
- Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
- Claude Zdanow named Managing Director in Miami, Florida
As part of the long-planned transition, Branislav Vajdic, Ph.D., BEAT Founder and current CEO, will move into the role of President. In this role, Dr. Vajdic will focus on further innovating on the groundbreaking BEAT vector-based technology, driving research and development efforts, and advancing artificial intelligence (AI) applications.
The BEAT core vector-based technology captures the heart's electrical signals from three dimensions to provide total heart intelligence. The first application of the BEAT technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The BEAT system is currently under review with the FDA.
With over 30 years of experience, Mr. Eno, age 57, is a passionate leader who has created go-to-market strategies for multiple breakthrough products including noninvasive FFRCT for diagnosing coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation, and intravascular brachytherapy. Before joining BEAT, Mr. Eno was Chief Executive Officer of Preview Medical, a diagnostic equipment company creating a new category of real-time, in vivo tissue classification for solid tumor cancers, using machine learning and proprietary optical signals. Previously, he was Senior Vice President of Marketing for HeartFlow, leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. Mr. Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa.
More on The PennZone
- YWCA Hanover Celebrates Opening of New Children's Learning Academy
- Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
- netElastic Announces vBNG And CGNAT 2.0 General Availability
- Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
- Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
Dr. Lance Myers Appointed as Chief AI Scientist
On September 24th BEAT announced the appointment of Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, as Chief Artificial Intelligence (AI) Scientist. In this newly created position, Dr. Myers will play a pivotal role in guiding how AI is applied to the Company's core technology.
Most recently, Dr. Myers served as AI Advisor to BEAT. Previously, he was the Head of Cardiovascular Devices at Verily Life Sciences (formerly Google Life Sciences), where he led a team developing a novel heart failure monitoring solution. Prior to that, he was the Head of Data Science at Verily and built a high-performance AI organization with teams in computational biology, medical device and biosensor algorithms, digital biomarkers, health informatics and digital pathology. He has also held leadership roles at XAI.health, Sentrian, VivoSense, Boston Neurosciences and Vivometrics. He currently serves as a board member for VivoSense and is on the scientific advisory boards of Acorai, XAI.health and Bryte. Dr. Myers received his PhD in Biomedical Engineering from the University of Cape Town in South Africa.
Media Contact
Company Name: HeartBeam, Inc.
Contact Person: Timothy Cruickshank
Email: ir.heartbeam.com
Phone: 408-899-4443
Website: www.HeartBeam.co m
Home Country: United States
Disclaimer and Disclosure: www. aibrandnetwork.com
Source: CorporateAds, LLC
0 Comments
Latest on The PennZone
- Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
- Dutch Mill Bulbs Launches Pink Ribbon Tulip Fundraise ~ National Breast Cancer Foundation, Inc.®
- SecureMaine 2026 is Here -- Thursday October 8th!
- Bluestone Laundromat Makes a Difference in the Archbald Community
- HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
- Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
- ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
- BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
- Ten Ten Ten Announces Maximizing Clinical Operations
- Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
- CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
- American Garden Rose Selections™ Announces 2027 Winners
- Crossroads4Hope Launches Blood Cancer Resource Hub
- Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
- NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
- Georgia's Magical Nights of Lights Bigger and Brighter for 2026
- Bicentennial Occult Outing Alternative History Video Series Launches for Spooky Season
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
- NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
- OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors